Must Watch These 5 Stocks: Parsley Energy (NYSE:PE), Immune Design Corp. (NASDAQ:IMDZ), IXYS Corp. (NASDAQ:IXYS), RCS Capital (NYSE:RCAP), Can-Fite BioPharma (NYSEMKT:CANF)


Parsley Energy (NYSE:PE) was downgraded by analysts at Wells Fargo & Co. from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Thursday. Parsley Energy, Inc. (NYSE:PE) in last trading activity increased 9.12% to close at $15.92. Company weekly performance is 38.31% while its quarterly performance stands at -21.42%. Parsley Energy, Inc. (NYSE:PE) is -38.05% away from its 52 week high.

Immune Design Corp. (NASDAQ:IMDZ) on Nov. 12 reported financial results for the third quarter ended September 30, 2014. IMDZ ended the third quarter of 2014 with $83.4 million in cash and cash equivalents compared to $18.0 million at the end of the second quarter. General and administrative expenses for the third quarter of 2014 were $4.1 million, compared to $1.1 million for the third quarter of 2013. Net loss for the third quarter of 2014 was $6.7 million, compared to $4.0 million for the third quarter 2013. On last trading day Immune Design Corp. (NASDAQ:IMDZ) increased 20.48% to close at $33.06. Its volatility for the week is 11.93% while volatility for the month is 8.79%. IMDZ’s EPS growth for past 5 years was 0.00%. Immune Design Corp. (NASDAQ:IMDZ) monthly performance is 4.52%.

IXYS Integrated Circuits Division (ICD), (NASDAQ: IXYS), announces the immediate availability of the IX3180 2.5A Gate Drive Optocoupler. The IX3180 combines IXYS ICD’s optocoupler expertise from its OptoMOS product line with its popular 600-Series of high current gate drivers. The optocoupler input is a light emitting diode which is then optically coupled to an integrated circuit containing a photo diode and high-speed, high current, push-pull power output. On last trading day IXYS Corp. (NASDAQ:IXYS) decreased -1.16% to close at $11.97. Its volatility for the week is 3.68% while volatility for the month is 3.80%. IXYS’s sales growth for past 5 years was 4.20% and its EPS growth for past 5 years was 30.10%. IXYS Corp. (NASDAQ:IXYS) monthly performance is 5.00%.

CEO of RCS Capital, Michael Weil stated,”The fundamentals driving the success of our business remain strong and unchanged. Our confidence in the long-term prospects for the company is resolute. There have been no reported accounting irregularities at RCS Capital, none, and the recent unfounded allegations reported in the press in connection with our Chairman, Nicholas S. Schorsch, should not have any material impact on the long-term strength of our business model or our operating results. RCS Capital Corporation (NYSE:RCAP) has 29.30% insider ownership while its institutional ownership stands at 44.50%. In last trading activity company’s stock closed at $11.00.

Can-Fite BioPharma Ltd. (NYSEMKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases reported that it will initiate a pre-clinical development program of its next generation drug CF602 for the indication of sexual dysfunction. On Friday shares of Can-Fite BioPharma Ltd. (NYSEMKT:CANF) closed at $3.41.


Leave a Reply

Your email address will not be published. Required fields are marked *